What is Chardan Capital’s Estimate for LXEO FY2025 Earnings?

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) – Stock analysts at Chardan Capital dropped their FY2025 earnings per share (EPS) estimates for Lexeo Therapeutics in a research report issued on Tuesday, March 25th. Chardan Capital analyst G. Livshits now anticipates that the company will post earnings per share of ($3.10) for the year, down from their prior estimate of ($2.30). Chardan Capital has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for Lexeo Therapeutics’ current full-year earnings is ($3.14) per share.

Lexeo Therapeutics (NASDAQ:LXEO) last released its quarterly earnings data on Monday, March 24th. The company reported ($0.78) EPS for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.09.

A number of other equities analysts have also recently issued reports on LXEO. Leerink Partners cut their target price on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating for the company in a research report on Monday, March 24th. HC Wainwright reissued a “buy” rating and set a $23.00 price target on shares of Lexeo Therapeutics in a research report on Wednesday. Finally, Royal Bank of Canada decreased their price objective on Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating on the stock in a research note on Tuesday. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $22.80.

Lexeo Therapeutics Trading Down 0.2 %

NASDAQ:LXEO opened at $4.10 on Friday. The company has a market capitalization of $135.57 million, a PE ratio of -1.30 and a beta of 3.85. Lexeo Therapeutics has a 52-week low of $2.32 and a 52-week high of $19.50. The stock has a fifty day simple moving average of $4.05 and a 200-day simple moving average of $6.58. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 0.01.

Institutional Investors Weigh In On Lexeo Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Janus Henderson Group PLC grew its holdings in Lexeo Therapeutics by 15.3% in the 4th quarter. Janus Henderson Group PLC now owns 4,339,254 shares of the company’s stock valued at $28,508,000 after buying an additional 576,059 shares during the period. Frazier Life Sciences Management L.P. purchased a new stake in Lexeo Therapeutics in the third quarter valued at approximately $11,307,000. Vestal Point Capital LP increased its position in Lexeo Therapeutics by 41.2% during the fourth quarter. Vestal Point Capital LP now owns 1,200,000 shares of the company’s stock worth $7,896,000 after purchasing an additional 350,000 shares during the last quarter. Woodline Partners LP raised its stake in Lexeo Therapeutics by 0.8% during the fourth quarter. Woodline Partners LP now owns 858,691 shares of the company’s stock worth $5,650,000 after purchasing an additional 6,730 shares during the period. Finally, Verition Fund Management LLC grew its stake in shares of Lexeo Therapeutics by 84.5% during the 3rd quarter. Verition Fund Management LLC now owns 777,320 shares of the company’s stock valued at $7,027,000 after buying an additional 355,928 shares during the period. Hedge funds and other institutional investors own 60.67% of the company’s stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.